---
id: influenza_106
category: organisms
tags: [influenza, oseltamivir, neuraminidase-inhibitors, H1N1, avian-flu]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Influenza

**Q:** What are the clinical features, diagnosis, treatment (including oseltamivir), and prevention of seasonal and avian influenza?

**A:**

## OVERVIEW

**Viruses:**
- **Influenza A** (subtypes: H1N1, H3N2, avian H5N1, H7N9)
- **Influenza B** (lineages: Victoria, Yamagata)
- **Influenza C** (mild, rare)

**Key Point:** **Influenza A = more severe**, causes pandemics (antigenic shift)

---

## CLINICAL FEATURES

**Typical Influenza:**
- **Abrupt onset** fever (38-40°C), chills
- **Myalgias, headache** (prominent)
- **Dry cough, sore throat**
- **Fatigue** (can persist weeks)

**Key Point:** **Abrupt fever + myalgias** = influenza

**Complications:**
- **Primary viral pneumonia** (ARDS)
- **Secondary bacterial pneumonia** (S. pneumoniae, S. aureus - including MRSA)
- **Myositis, rhabdomyolysis**
- **Myocarditis, pericarditis**
- **Encephalitis** (children - Reye syndrome if aspirin given)

---

## DIAGNOSIS

| **Test** | **Sensitivity** | **Turnaround** |
|----------|-----------------|----------------|
| **Rapid antigen (RIDT)** | **50-70%** | 15 min |
| **PCR (RT-PCR)** | **>95%** | 1-4 hours |

**Key Point:** **PCR = gold standard** (rapid antigen has low sensitivity)

---

## TREATMENT

**Neuraminidase Inhibitors:**

| **Agent** | **Dosing** | **Notes** |
|-----------|------------|-----------|
| **Oseltamivir (Tamiflu)** | **75 mg PO BID x 5 days** | **Preferred** (oral) |
| **Zanamivir (Relenza)** | **10 mg inhaled BID x 5 days** | Avoid if asthma/COPD |
| **Peramivir** | **600 mg IV x 1 dose** | If cannot tolerate PO |
| **Baloxavir (Xofluza)** | **40-80 mg PO x 1 dose** | Cap-dependent endonuclease inhibitor |

**Key Point:** **Oseltamivir = first-line** (oral, well-tolerated)

**Indications:**
- **Hospitalized patients**
- **High-risk** (age <2 or >65, pregnancy, chronic disease, immunocompromised)
- **Severe/progressive illness**

**Timing:**
- **Most effective if started <48 hours** of symptom onset
- **Still beneficial >48 hours** if hospitalized or high-risk

**Dosing Adjustments:**
- **Severe illness:** Consider oseltamivir 150 mg PO BID (double dose)
- **Renal impairment:** Adjust oseltamivir dose

---

## PREVENTION

**Vaccination:**
- **Inactivated influenza vaccine (IIV)** OR **Recombinant (RIV)** - all ages ≥6 months
- **Live attenuated (LAIV)** - ages 2-49 (NOT if immunocompromised, pregnancy)
- **Timing:** Annual (before flu season - October-November)

**Chemoprophylaxis (Post-Exposure):**
- **Oseltamivir** 75 mg PO daily x 7-10 days (unvaccinated high-risk exposed to confirmed case)

**Key Point:** **Vaccination = most effective prevention**

**Media:** None

**Sources:** [CDC 2024 - Influenza treatment guidelines]
